Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115681 | 0.84 | TACR3 (0.52) | DRD2DRD4 | |
| SCHEMBL6180467 | 0.81 | CHRM2 (0.37) | DRD2DRD4LTA4H | |
| SCHEMBL3205171 | 0.78 | PTGDR2 (0.39) | MEN1KMT2ACHRM4BCHE | |
| SCHEMBL4889901 | 0.75 | PTGDR2 (0.38) | DRD2DRD4MEN1KMT2ABCHE | |
| SCHEMBL8446486 | 0.74 | LTA4H (0.65) | DRD2DRD4BCHEACHEMAOB | |
| SCHEMBL5116054 | 0.74 | BCHE (0.47) | MEN1KMT2ABCHEACHEMAOB | |
| SCHEMBL5145288 | 0.73 | SLC6A2 (0.40) | — | |
| SCHEMBL7695896 | 0.72 | LTA4H (0.65) | BCHEACHELTA4H | |
| SCHEMBL9631914 | 0.72 | BCHE (0.54) | DRD2DRD4BCHEACHELTA4H | |
| SCHEMBL23182609 | 0.70 | ACHE (0.56) | BCHEACHESCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | claimed |
| US-7465751-B2 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | disclosed |
| EP-1583741-A1 | 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories, Limited (IN) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004056767-A1 | 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | CHRM3, CHRM1, CHRM5 | DRD2 233/4885DRD4 426/4885MEN1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.